Warning: I have nothing encouraging or positive to say in this latest installment of my small-cap biotech column featuring ResTORbio (TORC) — damn, that’s a stupid spelling — Trovagene (TROV), and Atossa Genetics (ATOS). I start in skeptical, glass-half-empty mode before going full-tilt “GET OFF MY LAWN!” You like that best, right?

ResTORbio said last week that the FDA agreed to its proposed design for Phase 3 clinical trials that use a less stringent primary endpoint than the one used by the company in its Phase 2 clinical trial. A less demanding primary endpoint means greater odds of clinical trial success, which in turn, means a higher likelihood that ResTORbio’s drug is approved. Or, so ResTORbio bulls will tell you.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy